Summary
A Phase III, open label, randomized, controlled, multicenter study to assess the safety and efficacy of the Study Drug monotherapy versus the physician’s choice to treat platinum-sensitive relapsed ovarian cancer.
Register to download
Embracing a Risk-based Approach
You may also be interested in:

Early Engagement Crucial to Develop Trial Design for Accelerated Schedule Vaccine Study
A case study describing PRA's involvement in an accelerated schedule vaccine study for poliomyelitis.
View Resource

HEALEY ALS Platform Trial Drives Innovation in ALS Clinical Research
Amyotrophic lateral sclerosis (ALS) is a lethal, relentlessly progressive neurodegenerative disease, and the most common adult-onset motor neuron…
Read Story

CSF Sampling
PRA understands how cerebrospinal fluid (CSF) sampling benefits our clients’ early phase trials. We regularly conduct CSF sampling to collect key PK…
View Resource
View all related content and resources for Study Design
Explore Insights